Abstract
Accumulating data from clinical practice hint that an alternative class of biologic agent may be the best choice when anti-TNF therapy for rheumatoid arthritis fails to produce the desired effect. Furthermore, evidence suggests that non-anti-TNF biologic agents should perhaps also be considered as the initial choice of biologic agent.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.